Enhertu Reimbursement Analysis: Navigating Cost-Effectiveness Challenges

By João L. Carapinha

June 5, 2025

The Dutch Healthcare Institute (ZIN) has recommended trastuzumab deruxtecan (Enhertu) for inclusion in the Netherlands’ basic insurance package for HER2-low metastatic breast cancer. This recommendation is contingent on a price reduction exceeding 68%. The DESTINY-Breast04 trial demonstrated a median overall survival (OS) benefit of 6.6 months compared to chemotherapy. Despite this efficacy, the incremental cost-effectiveness ratio (ICER) of €219,803 per quality-adjusted life year (QALY) far exceeds the Dutch threshold of €80,000, necessitating significant price concessions. The ZIN emphasizes concerns over missing quality-of-life (QoL) data and variability in HER2-low diagnostic standardization, which could impact real-world effectiveness and cost calculations.

Clinical and Economic Insights

Efficacy and Diagnostic Challenges

Trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate, has redefined treatment paradigms for HER2-low breast cancer, a subtype historically classified as HER2-negative. The DESTINY-Breast04 trial showed a 38% reduction in progression-free survival (PFS) risk (median PFS: 13.2 vs. 8.1 months) and a 36% OS improvement, establishing it as a first-line option post-endocrine therapy. However, HER2-low identification relies on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), with variability in testing methods leading to potential misclassification. The ZIN highlights the need for standardized diagnostics, aligning with the Ventana UltraView assay used in clinical trials, to ensure equitable patient access.

Cost-Effectiveness and Budget Impact

The ZIN’s cost-effectiveness analysis estimates a budget impact of €40.6 million annually by year three, treating approximately 475 patients. At current pricing, Enhertu’s lifetime treatment cost (€136,751) dwarfs chemotherapy (€41,902), driven by its €9,574 per-cycle list price. This aligns with broader European trends, where England’s NICE rejected Enhertu due to exceeding acceptable cost-effectiveness ranges. In Germany, similar debates have arisen, with the G-BA noting insufficient comparative data for HER2-mutated NSCLC.

Global Context and Policy Implications

Epidemiological and Health System Considerations

HER2-low breast cancer represents approximately 60% of HER2-negative cases, with higher prevalence in hormone receptor (HR)-positive tumors. The WHO’s Global Breast Cancer Initiative aims to reduce mortality by 2.5% annually, yet disparities persist. The five-year survival rate in high-income countries exceeds 90%, compared to only 40% in South Africa. Enhertu’s approval in the EU for HER2-low and HER2-ultralow tumors (April 2025) reflects shifting diagnostic thresholds, but affordability remains a barrier in lower-resource settings.

Enhertu Reimbursement Analysis and Pricing Dynamics

The ZIN’s demand for a more than 68% price reduction resonates with stringent European cost-containment strategies. In Germany, the G-BA evaluates therapies under §35a SGB V, often requiring comparative effectiveness data absent in single-arm trials. The Netherlands’ threshold of €80,000/QALY, adjusted for disease severity, contrasts with Germany’s implied threshold of approximately €90,000/QALY. These disparities highlight tensions between innovation incentives and fiscal sustainability, especially as developers explore label expansions into gastric and NSCLC indications.

Recommendations for Health Economics and Outcomes Research (HEOR)

  1. Real-World Evidence Generation: Post-marketing studies should address QoL gaps and long-term survival data absent from pivotal trials. Registries tracking HER2-low diagnostic consistency (e.g., IHC 1+ vs. 2+/ISH-) could optimize patient selection.
  2. Value-Based Pricing Models: Outcomes-based agreements, such as the Netherlands’ proposed two-year financial arrangement, could link reimbursement to real-world effectiveness while mitigating budget shocks.
  3. Diagnostic Harmonization: Collaboration between pathologists and payers, as seen in the Dutch HER2-low standardization initiative, is critical to ensuring equitable access and reducing geographic treatment disparities.

The Enhertu reimbursement analysis encapsulates the growing imperative for alignment between clinical innovation, health technology assessment (HTA) methodologies, and affordability safeguards in an era of precision oncology. As HER2-targeted therapies expand into earlier lines and novel subtypes, stakeholders must balance therapeutic promise with sustainable financing—a challenge epitomized by the Dutch ZIN’s cautious endorsement.

For a deeper background on these findings, refer to the original guidelines here.

Reference url

Recent Posts

thimerosal vaccine removal
      

Thimerosal Vaccine Removal: HHS Finalizes Decision

🩺 Is the removal of thimerosal from flu vaccines a step towards safer immunization or a move that could undermine public trust?

The recent decision by the U.S. Department of Health and Human Services to eliminate this mercury-based preservative has sparked a heated debate. While aiming to protect vulnerable populations, it raises questions about the impact on public perception and vaccine confidence.

Dive into the implications of this controversial policy shift and what it means for the future of vaccination practices.

#SyenzaNews #HealthcarePolicy #HealthEconomics

type 2 diabetes treatment
       

Comprehensive Review of Type 2 Diabetes Treatment and Diagnosis Strategies

🤔 Are you up to date with the latest strategies for managing Type 2 Diabetes?

A recent comprehensive review jumps into the evolving landscape of Type 2 diabetes treatment, emphasizing individualized care through lifestyle modifications, effective medications, and emerging therapies. Discover how personalized approaches can not only improve health outcomes but also mitigate complications associated with this chronic condition.

Curious to learn more? Click through for insights that could transform your understanding of diabetes management!

#SyenzaNews #HealthcareInnovation #HealthEconomics

Dutch Pharmacoeconomic Redesign
         

Dutch Pharmacoeconomic Redesign: Streamlined Structure and Enhanced Transparency for Drug Assessment

🌟 Are you ready for a transformation in pharmacoeconomic assessments?

The Dutch National Health Care Institute is set to unveil its **Pharmacoeconomic Redesign** on September 1, 2025, introducing a refined framework for evaluating drug reimbursement in the Netherlands. This innovative approach emphasizes clarity, transparency, and methodological rigor, ensuring more informed decisions in healthcare.

Dive into the article to discover how these changes will impact market access and elevate standards in health economics!

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.